PUBLISHER: The Business Research Company | PRODUCT CODE: 1559160
PUBLISHER: The Business Research Company | PRODUCT CODE: 1559160
Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2024
Empagliflozin, dapagliflozin, and canagliflozin are medications known as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, primarily prescribed for managing type 2 diabetes mellitus. These oral medications are part of a comprehensive diabetes treatment plan that also involves diet, exercise, and potentially other medications.
The specific types of these SGLT-2 inhibitors include empagliflozin, dapagliflozin, and canagliflozin. Empagliflozin is used mainly to reduce blood sugar levels in adults with type 2 diabetes by aiding the kidneys in expelling glucose through urine. These medications are available in various applications, including application I, application II, application III, and application IV, and can be purchased through hospitals and pharmacies.
The empagliflozin, dapagliflozin and canagliflozin market research report is one of a series of new reports from The Business Research Company that provides empagliflozin, dapagliflozin and canagliflozin market statistics, including empagliflozin, dapagliflozin and canagliflozin industry global market size, regional shares, competitors with an empagliflozin, dapagliflozin and canagliflozin market share, detailed empagliflozin, dapagliflozin and canagliflozin market segments, market trends, and opportunities, and any further data you may need to thrive in the empagliflozin, dapagliflozin and canagliflozin industry. This empagliflozin, dapagliflozin and canagliflozin research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.41 billion in 2023 to $9.64 billion in 2024 at a compound annual growth rate (CAGR) of 2.4%. The growth observed in the historical period can be linked to the global rise in type 2 diabetes prevalence, greater awareness of the benefits of SGLT2 inhibitors, an expanding elderly population, increasing obesity rates, and a heightened focus on personalized medicine.
The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $10.78 billion in 2028 at a compound annual growth rate (CAGR) of 2.8%. The anticipated growth during the forecast period is driven by a rising demand for oral diabetes medications, growing investments in diabetes research and drug development, increased healthcare spending, heightened awareness and diagnosis of pre-diabetic conditions, and a greater emphasis on combination therapies. Key trends expected in the forecast period include advancements in technology, combination therapies, telehealth, health data analytics, and enhanced patient data security.
The growing incidence of diabetes is projected to drive the expansion of the empagliflozin, dapagliflozin, and canagliflozin market in the future. Diabetes is a chronic condition characterized by elevated blood sugar levels due to either insufficient insulin production or the body's poor use of insulin. Contributing factors to the rise in diabetes include sedentary lifestyles, poor dietary habits, genetic factors, urbanization, an aging population, limited healthcare access, and increasing obesity rates worldwide. Empagliflozin, dapagliflozin, and canagliflozin help manage diabetes by lowering blood sugar through the inhibition of sodium-glucose co-transporter-2 (SGLT2) in the kidneys, facilitating glucose excretion via urine. For example, the International Diabetes Federation projected that the number of people with diabetes would reach 643 million by 2030 and 783 million by 2045. This growing prevalence is fueling the demand for empagliflozin, dapagliflozin, and canagliflozin.
Key players in the empagliflozin, dapagliflozin, and canagliflozin markets are concentrating on creating innovative products, such as treatments for pediatric type-2 diabetes, to cater to a wider patient base and enhance their market presence. Pediatric type-2 diabetes treatment involves managing blood sugar through lifestyle modifications, medications, and occasionally insulin therapy specifically designed for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 and older with type 2 diabetes. This approval followed positive results from the T2NOW Phase III clinical trial, one of the largest pediatric type-2 diabetes studies, demonstrating that Farxiga significantly reduced HbA1c levels compared to a placebo. The safety profile of Farxiga in this age group was consistent with its profile in adults with type 2 diabetes. This milestone is significant as oral treatment options for pediatric type-2 diabetes have been scarce, highlighting AstraZeneca's dedication to advancing treatments for cardiovascular, renal, and metabolic diseases.
In May 2021, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired the rights to the trademarks of the diabetes drug brands Oxra, Oxramet, and Oxraduo from AstraZeneca plc for an undisclosed amount. This acquisition will boost Sun Pharma's market share, enhance its position in the diabetes treatment sector, and provide additional treatment options for patients across India. AstraZeneca plc is a UK-based pharmaceutical company that offers diabetes medications, including dapagliflozin.
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2023. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the empagliflozin, dapagliflozin and canagliflozin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The empagliflozin, dapagliflozin and canagliflozin market consists of sales of jardiance, glyxambi, synjardy, farxiga, and invokamet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on empagliflozin, dapagliflozin and canagliflozin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for empagliflozin, dapagliflozin and canagliflozin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The empagliflozin, dapagliflozin and canagliflozin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Empagliflozin; Dapagliflozin; Canagliflozin
- 2) By Application: Application I; Application II; Application III; Application IV
- 3) By Channel: Hospital; Pharmacy
- Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Empagliflozin, Dapagliflozin And Canagliflozin Market Characteristics
3. Empagliflozin, Dapagliflozin And Canagliflozin Market Trends And Strategies
4. Empagliflozin, Dapagliflozin And Canagliflozin Market - Macro Economic Scenario
- 4.1. Impact Of High Inflation On The Market
- 4.2. Ukraine-Russia War Impact On The Market
- 4.3. COVID-19 Impact On The Market
5. Global Empagliflozin, Dapagliflozin And Canagliflozin Market Size and Growth
- 5.1. Global Empagliflozin, Dapagliflozin And Canagliflozin Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
- 5.2. Global Empagliflozin, Dapagliflozin And Canagliflozin Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
- 5.3. Global Empagliflozin, Dapagliflozin And Canagliflozin Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Empagliflozin, Dapagliflozin And Canagliflozin Market Segmentation
- 6.1. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Empagliflozin
- Dapagliflozin
- Canagliflozin
- 6.2. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Application I
- Application II
- Application III
- Application IV
- 6.3. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospital
- Pharmacy
7. Empagliflozin, Dapagliflozin And Canagliflozin Market Regional And Country Analysis
- 7.1. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 7.2. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market
- 8.1. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.3. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.4. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Empagliflozin, Dapagliflozin And Canagliflozin Market
- 9.1. China Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 9.2. China Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.3. China Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.4. China Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Empagliflozin, Dapagliflozin And Canagliflozin Market
- 10.1. India Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.2. India Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.3. India Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market
- 11.1. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 11.2. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.3. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.4. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market
- 12.1. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.2. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.3. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market
- 13.1. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.2. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.3. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market
- 14.1. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 14.2. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.3. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.4. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market
- 15.1. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 15.2. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.3. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.4. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Empagliflozin, Dapagliflozin And Canagliflozin Market
- 16.1. UK Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.2. UK Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.3. UK Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market
- 17.1. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.2. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.3. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Empagliflozin, Dapagliflozin And Canagliflozin Market
- 18.1. France Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.2. France Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.3. France Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market
- 19.1. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.2. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.3. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market
- 20.1. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.2. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.3. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market
- 21.1. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 21.2. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.3. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.4. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market
- 22.1. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.2. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.3. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Empagliflozin, Dapagliflozin And Canagliflozin Market
- 23.1. North America Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 23.2. North America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.3. North America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.4. North America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Empagliflozin, Dapagliflozin And Canagliflozin Market
- 24.1. USA Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 24.2. USA Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.3. USA Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.4. USA Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market
- 25.1. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 25.2. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.3. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.4. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Empagliflozin, Dapagliflozin And Canagliflozin Market
- 26.1. South America Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 26.2. South America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.3. South America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.4. South America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market
- 27.1. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.2. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.3. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market
- 28.1. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 28.2. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.3. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.4. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market
- 29.1. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
- 29.2. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.3. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.4. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Landscape And Company Profiles
- 30.1. Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Landscape
- 30.2. Empagliflozin, Dapagliflozin And Canagliflozin Market Company Profiles
- 30.2.1. Pfizer Inc.
- 30.2.1.1. Overview
- 30.2.1.2. Products and Services
- 30.2.1.3. Strategy
- 30.2.1.4. Financial Performance
- 30.2.2. Merck & Co. Inc.
- 30.2.2.1. Overview
- 30.2.2.2. Products and Services
- 30.2.2.3. Strategy
- 30.2.2.4. Financial Performance
- 30.2.3. Sanofi S.A.
- 30.2.3.1. Overview
- 30.2.3.2. Products and Services
- 30.2.3.3. Strategy
- 30.2.3.4. Financial Performance
- 30.2.4. Bristol-Myers Squibb Company
- 30.2.4.1. Overview
- 30.2.4.2. Products and Services
- 30.2.4.3. Strategy
- 30.2.4.4. Financial Performance
- 30.2.5. AstraZeneca PLC
- 30.2.5.1. Overview
- 30.2.5.2. Products and Services
- 30.2.5.3. Strategy
- 30.2.5.4. Financial Performance
- 30.2.1. Pfizer Inc.
31. Empagliflozin, Dapagliflozin And Canagliflozin Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline plc
- 31.2. Eli Lilly and Company
- 31.3. Boehringer Ingelheim GmbH
- 31.4. Teva Pharmaceutical Industries Ltd.
- 31.5. Astellas Pharma Inc.
- 31.6. MSN Laboratories Private Limited
- 31.7. Dr. Reddy's Laboratories Ltd.
- 31.8. Aurobindo Pharma Limited
- 31.9. Cipla Limited
- 31.10. Cadila Healthcare Limited
- 31.11. Apotex Inc.
- 31.12. Lupin Limited
- 31.13. Biocon Limited
- 31.14. Alkem Laboratories Ltd.
- 31.15. Torrent Pharmaceuticals Ltd.
32. Global Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Benchmarking
33. Global Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Empagliflozin, Dapagliflozin And Canagliflozin Market
35. Empagliflozin, Dapagliflozin And Canagliflozin Market Future Outlook and Potential Analysis
- 35.1 Empagliflozin, Dapagliflozin And Canagliflozin Market In 2028 - Countries Offering Most New Opportunities
- 35.2 Empagliflozin, Dapagliflozin And Canagliflozin Market In 2028 - Segments Offering Most New Opportunities
- 35.3 Empagliflozin, Dapagliflozin And Canagliflozin Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
